We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Brain Imaging and Mental Disorders of Aging Intervention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00267163
Recruitment Status : Completed
First Posted : December 20, 2005
Last Update Posted : August 29, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Cognition Disorders Drug: donepezil Drug: Placebo Phase 4

Detailed Description:

Studies to date show that pictures of the brain using PET (positron emission tomography) scan measures predict memory decline in people with genetic risks for developing AD. They have also been shown to predict memory decline in people with mild memory complaints. These findings are consistent with other evidence that the changes of Alzheimer's Disease (AD) begin years before the doctor can confirm a diagnosis.

In this study, PET and genetic risk studies will be performed in people with mild memory complaints. A total of 138 participants (age 40 to 90 years) who are at risk for further memory decline will be enrolled. They will be randomized (like the flip of a coin) to one of two treatment groups, donepezil (a medication to treat mild AD) or placebo, and followed 18 months for evidence of future decline. Participants will receive magnetic resonance imaging (MRI) scans, PET scans, genetic risk assessment for Alzheimer's Disease, and neuropsychological assessments. Repeat brain imaging studies will be performed at the end of the 18-month treatment trial.

These procedures will allow researchers to explore how baseline brain function and genetic risk for AD onset influences brain metabolic rate and memory decline, and treatment outcome. Participants receiving donepezil are expected to show less evidence of decline than those receiving placebo. This project will expand a growing research program in early detection and prevention of AD, designed (1) to identify persons without memory complaints who are most likely to benefit from early intervention and (2) to provide an objective way to monitor the activity in the brain.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Brain Imaging and Mental Disorders of Aging Intervention
Study Start Date : September 2000
Primary Completion Date : July 2007
Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Donepezil
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1. Drug: donepezil
Placebo Comparator: 2. Drug: Placebo


Outcome Measures

Primary Outcome Measures :
  1. Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing [ Time Frame: at 18 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Agreement to participate in a 18 month clinical trial
  • NIMH diagnostic criteria for age-associated memory impairment (AAMI)
  • Age 40 to 90 years
  • MMSE score between 24 and 30 (unless < 8 years of educational achievement)
  • No significant cerebrovascular disease - modified Ischemic Score of < 4
  • The following medications are allowed if stable for > 1 month: antidepressants (without anticholinergic effects) if not currently depressed and no history of major depression for 2 years; estrogen replacement therapy; thyroid replacement therapy as long as patient is euthyroid
  • On entering the study, there must be a family member or potential caregiver available in case the patient develops cognitive impairment that interferes with independent study participation.
  • Memory and verbal fluency cut-off scores increasing the probability of incipient dementia (Buschke-Fuld - 34; verbal fluency - 46 for letters, 7 for categories; Benton Visual Retention - 5)
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Screening laboratory tests and ECG without significant abnormalities that might interfere with the study

Exclusion Criteria:

  • Diagnosis of possible or probable AD or any other dementia (e.g., vascular, Lewy body, frontotemporal)
  • Evidence of neurologic or other physical illness that could produce cognitive deterioration, including Parkinson's disease; volunteers with a history of TIAs, carotid bruits, or lacunes on MRI scan will be excluded
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension, history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer
  • Such current major psychiatric disorders as mania, according to DSMIV criteria, within the previous two years
  • Current diagnosis or history of alcoholism or drug dependence
  • Evidence of untreated depression
  • Use of any of the following drugs: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin; vitamins other than the standard multivitamin supplement, ginkgo biloba, and any nutraceuticals will not be allowed; once enrolled in the study, occasional chloral hydrate use will be allowed, but discouraged, for insomnia
  • Use of any investigational drugs within the previous month or longer, depending on drug half-life
  • Contraindication for MRI scan (e.g., metal in body, claustrophobia)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267163


Locations
United States, California
UCLA, The Semel Institute for Neuroscience and Human Behavior
Los Angeles, California, United States, 90024
Sponsors and Collaborators
National Institute on Aging (NIA)
Investigators
Principal Investigator: Gary W. Small, MD University of California, Los Angeles, Neuropsychiatric Institute
More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00267163     History of Changes
Other Study ID Numbers: IA0090
9R01AG018487-06 ( U.S. NIH Grant/Contract )
First Posted: December 20, 2005    Key Record Dates
Last Update Posted: August 29, 2008
Last Verified: August 2008

Keywords provided by National Institute on Aging (NIA):
Alzheimer's disease
Mild Cognitive Impairment

Additional relevant MeSH terms:
Disease
Mental Disorders
Psychotic Disorders
Cognition Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Neurocognitive Disorders
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents